Thordur Gunnarsson

Thordur Gunnarsson

Auto-generated profile, based on publicly available information

Thordur Gunnarsson

Faculty of Medicine, Lund University, Lund, Sweden; Department of Surgery, Helsingborg Hospital, Helsingborg, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
TGThordur Gunnarsson
Thordur Gunnarsson
HLHans Lindgren
Hans Lindgren
AGAnders Gottsäter
Anders Gottsäter
HPHåkan Pärsson
Håkan Pärsson

12 January 2023 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
TGThordur Gunnarsson
Thordur Gunnarsson
SBStefan Bergman
Stefan Bergman
HPHåkan Pärsson
Håkan Pärsson
AGAnders Gottsäter
Anders Gottsäter
HLHans Lindgren
Hans Lindgren
Primary stenting of the superficial femoral artery (SFA) in intermittent claudication (IC) has been shown to increase health related quality of life (HRQoL) after 12 and 24 months. An extended follow up of HRQoL 36 and 60 months after randomisation is presented. A multicentre randomised controlled trial was conducted at seven vascular clinics in Sweden between 2010 and 2020. One hundred patients randomised to either primary stenting and best medical treatment (BMT; n = 48) or BMT alone (n = 52) were followed for 60 months. HRQoL, assessed by the Short Form 36 Health Survey (SF-36) and EuroQoL 5 dimensions (EQ5D) 36 and 60 months after randomisation, was the primary outcome. Walking Impairment Questionnaire (WIQ) score, re-interventions, progression to chronic limb threatening ischaemia (CLTI), amputation, and death were secondary outcomes. At the 36 month follow up, the stent group (n = 32) had statistically significantly better scores in the SF-36 domain "Role Physical" (p = .023) and the Physical Component Summary (p = .032) compared with the control group (n = 30); however, there was no statistically significant difference in EQ5D scores (p = .52). WIQ was statistically significantly better in the stent group compared with the control group (p = .029) at 36 months. At the 60 month follow up, no statistically significant difference in HRQoL was seen between patients in the stent (n = 31) and control groups (n = 32). Crossover from the control group to the stent group was 25% at 60 months. There were no differences in progression to CLTI, amputation (2.1% vs. 1.9%), or mortality (14.6% vs. 15.4%) between groups. In patients with IC caused by isolated SFA lesions, primary stenting conferred benefits to HRQoL until 36 months from treatment vs. BMT alone, but these benefits were no longer detectable at 60 months, where a high crossover rate affected the power of the final analysis.

7 March 2025 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
TGThordur S. Gunnarsson
Thordur S. Gunnarsson
SBStefan Bergman
Stefan Bergman
HPHåkan Pärsson
Håkan Pärsson
AGAnders Gottsäter
Anders Gottsäter
HLHans Lindgren
Hans Lindgren
This study aimed to report changes in the annual incidence of invasive treatment, changes in invasive treatment modalities, and sex differences in patients treated for intermittent claudication (IC) due to infra-inguinal lesions in Sweden between 2009 and 2022. Data were collected from the Swedish Vascular Registry (Swedvasc), including all registrations of invasive treatment for infra-inguinal IC in Sweden between 2009 and 2022. The annual incidence of invasive treatments showed no statistically significant change between 2009 and 2022 (p = .21). The proportion of open surgery decreased from 38.1% in 2009 to 23.4% in 2022 (p < .001). Endovascular and hybrid interventions increased from 56.9% to 69.7% (p < .001) and from 4.8% to 7.0% (p < .001), respectively, between 2009 and 2022 according to time trend analysis. The decrease in open surgery was due to a reduction in bypass surgery from 18.8% in 2009 to 4.0% in 2022 (p < .001). The proportion of common femoral artery thromboendarterectomy remained unchanged (p = .24). During the study period, 42.7% of invasive treatments were performed in women. Open surgery was more frequently performed in men than women during the study period (32.5% vs. 24.0%; p < .001). However, endovascular intervention was statistically significantly more often performed in women than men during the study period (70.7% vs. 61.6%; p < .001). The annual incidence of invasive treatment for infra-inguinal IC in Sweden was unchanged between 2009 and 2022. The proportion of endovascular interventions increased and accounted for 70% of invasive treatments in 2022, whereas bypass surgery decreased by 79%. Women were more often treated with endovascular intervention than men.

22 May 2023 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
TGT. Gunnarsson
T. Gunnarsson
SBS. Bergman
S. Bergman
HPH. Pärsson
H. Pärsson
AGA. Gottsäter
A. Gottsäter
HLH. Lindgren
H. Lindgren

16 September 2025 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
TGT.S. Gunnarsson
T.S. Gunnarsson
SBS. Bergman
S. Bergman
HPHåkan Pärsson
Håkan Pärsson
AGA. Gottsäter
A. Gottsäter
HLH. Lindgren
H. Lindgren

16 March 2023 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
TGThordur Gunnarsson
Thordur Gunnarsson
AGAnders Gottsäter
Anders Gottsäter
HLHans Lindgren
Hans Lindgren